

11<sup>th</sup> International Conference on

# Alzheimers Disease & Dementia

May 24-25, 2018 | Vienna, Austria

## Protective effects of phycobiliprotein on streptozotocin induced behaviour and biochemical deficits in experimental model of Alzheimer's disease

Madhunika Agrawal<sup>1</sup>, Yamini P<sup>1</sup>, Seema Bansal<sup>2</sup> and Kanwaljit Chopra<sup>1</sup><sup>1</sup>Panjab University, India<sup>2</sup>Postgraduate Institute of Medical Education and Research, India

The present study was designed to explore the neuroprotective efficacy of a promising antioxidant and anti-inflammatory phycobiliprotein (PB) against intracerebroventricular (ICV)-streptozotocin (STZ) induced cognitive impairment in rats. STZ (3 mg/kg) was introduced in rats' brains on the 1st and 3rd day, bilaterally followed by treatment with PB or rivastigmine for 28 days. Estimation of alteration in the behaviour of treated and untreated groups of rats were done by Morris water maze (MWM), elevated plus maze and open field test. Afterwards, the rats were sacrificed and brains were harvested for the evaluation of various biochemical parameters in post mitochondrial supernatant fractions of cerebral cortex and hippocampus. The levels of several oxidative stress (superoxide dismutase-SOD, catalase-CAT, lipid peroxidation-LPO) and inflammatory (TNF- $\alpha$ , NF- $\kappa$ B) biomarkers were analyzed and the activity towards acetylcholinesterase was also investigated by choline acetyltransferase (ChAT) assay. The amelioration of ICV-STZ induced spatial learning and memory impairment by PB could be associated, partially, to the downregulation of NF- $\kappa$ B activity and the mitigation of expression of neuroinflammatory cytokines, along with modulation of cholinesterase, suggesting that PB may be explored further as a potent candidate for Alzheimer's disease therapy.

madhunika21@gmail.com

Notes: